AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01312233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual Care
Description: Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12-week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity-low amplitude or low velocity-variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
Study NCT01312233 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shared Care
Description: Participants allocated to Shared Care receive co-managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
Study NCT03671564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan was administered orally once daily on Days 1 to 14 in a 28-day cycle.
Study NCT00805870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (omega-3-acid ethyl esters)
Description: Lovaza, 3 grams per day for 65 days
Study NCT00805870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Germ Oil
Description: Wheat germ oil, 3 grams/day for 65 days
Study NCT04869319 — intervention group
Intervention type: BEHAVIORAL
Intervention: MyChart message
Description: Message subjects through MyChart to follow-up with their provider to schedule a follow up HbA1C test.
Study NCT03281187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nasotestt 5 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
Study NCT03281187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasotestt 5 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
Study NCT03281187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Androgel 50 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
Study NCT03281187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgel 50 mg
Description: The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
Study NCT03281187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasotestt Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
Study NCT03281187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasotestt Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
Study NCT03281187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgel Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
Study NCT03281187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgel Placebo
Description: The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
Study NCT03633799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VeraCept
Description: VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method
Study NCT00033462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00497198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
Study NCT00497198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of MCI-196 Tablet
Description: Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
Study NCT04417972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR7280
Description: treatment
Study NCT04417972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR7280
Description: treatment
Study NCT04417972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: blank control
Study NCT04417972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: blank control
Study NCT01202383 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Household-based water treatment with NADCC tablets
Description: Study participants will be supplied with tablets and encouraged to use them for treating their water daily
Study NCT00955734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early motion
Description: One set of patients will begin wrist motion at 1 week after surgery.
Study NCT00955734 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immobilization
Description: This set of patients will be casted for 6 weeks after surgery.
Study NCT01832103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145
Study NCT00957788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NST-001
Description: Comparison of different dosages of drug.
Study NCT01830881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
Study NCT01830881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Study NCT01830881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: 800 mg oral ibuprofen 30-60 minutes prior to procedure
Study NCT01830881 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Cherry syrup
Description: 5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
Study NCT01830881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: injection of 20 mL 1% lidocaine without epinephrine
Study NCT01830881 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: injection of 20 mL 1% lidocaine without epinephrine
Study NCT02867969 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Motor training
Description: The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
Study NCT01619046 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GreenGene™ F and an approved recombinant Factor VIII product
Description: one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate \< 10 mL/min
Study NCT01619046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
Study NCT01619046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra-venous infusion,~On-demand safety and efficacy substudy:~minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg
Study NCT01619046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GreenGene™ F
Description: intra venous infusion,~Surgical substudy:~Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.~Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level.
Study NCT02038764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02038764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose A
Description: Multiple SC Doses
Study NCT02038764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose B
Description: Multiple SC Doses
Study NCT02038764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose C
Description: Multiple SC Doses
Study NCT02038764 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06342674 Dose D
Description: Multiple SC Doses
Study NCT01989559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M) Peptide Vaccine
Description: Given SC
Study NCT03729570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePrEP
Description: Participants will have a baseline teleconsultation with a site study clinician who will be responsible for prescribing PrEP as indicated. They will be offered a 1-month check-in and telemedicine consultations at 3, 6, 9 and 12 months. Participants will complete home specimen collection for laboratory tests for each consultation. The virtual study visit consists of surveys, specimen collection, and a telemedicine consultation.
Study NCT02794701 — intervention group
Intervention type: OTHER
Intervention: People with silicosis
Study NCT00847782 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: 1 day
Study NCT01989559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16 E7:12-20 Peptide Vaccine
Description: Given SC
Study NCT01989559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02811094 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: polymerase chain reaction (PCR) technique of blood transcriptome analysis
Description: this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
Study NCT01305096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Description: 6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
Study NCT01161693 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: TROOP® elevation pillow
Description: Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
Study NCT01161693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TROOP® elevation pillow
Description: designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
Study NCT04192630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CVisc50 OVD
Description: Bausch + Lomb CVisc50 Cohesive OVD
Study NCT04192630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProVisc OVD
Description: ProVisc OVD
Study NCT04192630 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract Surgery
Study NCT04192630 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Cataract Surgery
Study NCT03653663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: Subjects are treated with 20 mg simvastatin for 8 weeks
Study NCT03653663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Subjects are treated with placebo for 8 weeks
Study NCT00204308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination tenofovir-emtricitabine
Description: Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
Study NCT01684995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief physician advice
Description: Brief physician advice to quit smoking
Study NCT01684995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief physician advice
Description: Brief physician advice to quit smoking
Study NCT01684995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: nicotine patch
Study NCT01684995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch
Study NCT01684995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individually Tailored Behavioral Skills training
Description: Individually tailored behavioral skills training for smoking cessation
Study NCT03562455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VRSim 3.0
Description: VRSim 3.0 is a virtual reality training module.
Study NCT03562455 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Wheelchair Training
Description: A therapist will be used to train power wheelchair users.
Study NCT02952573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42756493
Description: Once daily dosing
Study NCT02952573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
Study NCT02571621 — intervention group
Intervention type: DEVICE
Intervention: Combitube
Description: Intubation with Combitube
Study NCT01185509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT01185509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study NCT00800306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
Study NCT00800306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dobutamine
Description: Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
Study NCT03268824 — intervention group
Intervention type: DEVICE
Intervention: Electroencephalogram (EEG)
Description: Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
Study NCT03268824 — intervention group
Intervention type: DEVICE
Intervention: Diffusion Tensor imaging
Description: We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
Study NCT03268824 — intervention group
Intervention type: OTHER
Intervention: Language assessment
Description: The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
Study NCT00792376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
Study NCT00792376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
Study NCT00792376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac
Description: diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
Study NCT02247635 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy lifestyle and adherence
Description: Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake \<30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.~The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care
Study NCT03780803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home cardiac rehabilitation and respiratory rehabilitation
Study NCT04583683 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet with Fortimel (Nutricia) supplementation
Description: Patients will undergo a very low calorie diet
Study NCT04583683 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metabolic Surgery
Description: Patients will undergo metabolic surgery
Study NCT04205929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Study NCT04205929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Study NCT03102658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Administration of study drug
Study NCT03102658 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Administration of study drug
Study NCT04116944 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The ecologically-valid resistance exercise training was designed according to World Health Organization and American College of Sports Medicine guidelines. The eight-week, twice-weekly intervention was designed to be performed at a moderate intensity. The resistance of each exercise was such that when participants could successfully complete 2 sets of 12 repetitions at a certain load, the resistance was increased incrementally up to 5% for the following session. Exercise sessions were scheduled with at least one day of rest between sessions. The eight exercises included the barbell squat, barbell bench press, hexagon bar deadlift, dumbbell shoulder lateral raise, barbell bent over rows, dumbbell lunges, dumbbell curls, and abdominal crunches.
Study NCT04116944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: Participants randomized to the delayed-start wait-list condition completed questionnaires once-weekly. The investigator sent a weekly email to the participant providing links to the questionnaires. Participants that completed the eight-week wait-list condition were offered the eight weeks of RET either immediately upon completion, or later at a time of their convenience while the trial was ongoing. Each participant randomized to the eight-week wait-list also completed two 30-minute bouts of seated quiet rest in an empty room at weeks one and eight.
Study NCT00547690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and Strengthening
Description: Acupuncture and strengthening
Study NCT00547690 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Strengthening Alone
Description: Strengthening training program
Study NCT00655733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-004
Description: HMPL-004 1200 mg/d
Study NCT00655733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1200 mg/d
Study NCT01335217 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcutaneous Electrical Nerve Stimulator (TENS)
Description: External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
Study NCT03560726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management
Description: Cognitive behavioral stress management is a well-established, practical intervention that combines elements of cognitive behavioral therapy with techniques designed to improve coping skills, social support, communication, and relaxation/mindfulness.
Study NCT00312065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of reflective heat shield to thermistor probe
Study NCT02946073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Study NCT02946073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo